• Seeking Alpha

Communiqué de presse : Wayrilz de Sanofi est approuvé aux États-Unis comme premier inhibiteur de BTK pour la thrombocytopénie immune

Seeking Alpha / 1 hour from now 1 Views

Wayrilz de Sanofi est approuvé aux États-Unis comme premier inhibiteur de BTK pour la thrombocytopénie immune

Read more
  • Source:
  • GlobeNewswire - News about Public Companies
Previous post
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Next post
Purepeak: Koreaans antiverouderingsmerk uitverkoren door Europese apotheken

Comments

Just Posted

  • Prime Drink Group Provides Bi-Weekly MCTO Status Report

    3 hours from now

  • Groupe Prime Drink fournit un rapport bihebdomadaire sur le statut du MCTO

    3 hours from now

  • Payment of dividends to BDR holders

    3 hours from now

  • Aja Health and Wellness Inc. Announces Agreement for the Purchase of Assets of Canadian Travel and Doctors Clinics Inc., Announces Share Subscription Agreement with GEM Global Yield LLC SCS, and Provides Update on Delay in Filing Financial Statements

    3 hours from now

  • Aura Announces a Change in the Company’s BDRs

    3 hours from now

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Reviews

Categories

  • Seeking Alpha 748

Categories

  • Seeking Alpha 748

Pages

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Copyright News That Move � 2018. All Rights Reserved

  • Seeking Alpha
  • Trade Halts